Xu Z, Zhang S, Nian F, et al. - A glycolysis-related gene signature to predict survival of patients with lung squamous cell carcinoma (LUSC) was built in this study, as well as new therapeutic targets were explored. Using the Cancer Genome Atlas database, mRNA expression and clinical data of 550 patients with LUSC were collected. Via Gene Set Enrichment Analysis, glycolysis genes were found. Five glycolysis-related genes signature (HKDC1, AGL, ALDH7A1, SLC16A3, and MIOX) was created to compute each patient's risk score. As per the risk score, patients were categorized into high- and low-risk groups; overall survival significantly varied between the two groups. As demonstrated by ROC curves, an AUC of 0.707 and 0.651 was generated for the training and validation cohorts, respectively. To clarify the link between glycolysis and LUSC, this gene signature was developed. Not only a good performance in assessing patients’ survival with LUSC was shown by this model, but also it offers new biomarkers for targeted therapy.